公开(公告)号：US20160304504A1

公开(公告)日：2016-10-20

申请号：US15101373

申请日：2014-11-25

Applicant: AMGEN INC.

Inventor： Mary CHAVES ,  Matthew BIO ,  Matthew PETERSON

IPC: C07D409/14 ,  C07C309/30 ,  C07C309/04

CPC classification number: C07D409/14 ,  C07B2200/13 ,  C07C309/04 ,  C07C309/30

Abstract: The present invention relates to crystalline forms and co-crystal forms of pharmaceutically acceptable salts of the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine (AMG 900, and pharmaceutical compositions comprising said crystalline and co-crystal forms thereof. The invention further provides uses of the crystalline forms and compositions, to treat cancer, including various types of solid tumors and hematologic cancer including myeloma and leukemia.

Abstract translation: 本发明涉及化合物N-（4 - （（3-（2-氨基-4-嘧啶基）-2-吡啶基）氧基）苯基）-4-甲基苯甲酸的药学上可接受的盐的结晶形式和共晶形式， （4-甲基-2-噻吩基）-1-酞嗪胺（AMG 900和包含其结晶和共晶形式的药物组合物）本发明还提供了结晶形式和组合物用于治疗癌症的用途，包括各种类型 实体肿瘤和血液癌，包括骨髓瘤和白血病。

公开(公告)号：US20240199550A1

公开(公告)日：2024-06-20

申请号：US18416741

申请日：2024-01-18

Applicant: Amgen Inc. ,  Cytokinetics, Inc.

Inventor： Henry MORRISON ,  Sheng CUI ,  Kyle QUASDORF ,  Evelyn YANEZ ,  Bin Peter QUAN ,  Ron C. KELLY ,  Sebastien CAILLE ,  Lingyun XIAO ,  David PEARSON ,  Jaclyn RAEBURN ,  Alisa GOLIGHTLY ,  Bradley MORGAN ,  Matthew PETERSON ,  Alex EBERLIN ,  Alexander OBLEZOV

IPC: C07D213/75

CPC classification number: C07D213/75 ,  C07B2200/13

Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.

公开(公告)号：US20180244696A1

公开(公告)日：2018-08-30

申请号：US15966157

申请日：2018-04-30

Applicant: AMGEN, INC.

Inventor： David BAUER ,  Matthew BIO ,  Melanie COOKE ,  Katrina W. COPELAND ,  Matthew PETERSON ,  Michele POTASHMAN ,  Roman SHIMANOVICH ,  Helming TAN

IPC: C07D519/00 ,  A61K31/52 ,  C07C57/145 ,  C07C57/10 ,  C07C55/12 ,  C07C55/10 ,  C07C275/02

CPC classification number: C07D519/00 ,  A61K31/52 ,  C07B2200/13 ,  C07C55/10 ,  C07C55/12 ,  C07C57/10 ,  C07C57/145 ,  C07C275/02

Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

公开(公告)号：US20170029443A1

公开(公告)日：2017-02-02

申请号：US15293511

申请日：2016-10-14

Applicant: AMGEN, INC.

Inventor： David BAUER ,  Matthew BIO ,  Melanie COOKE ,  Katrina W. COPELAND ,  Matthew PETERSON ,  Michele POTASHMAN ,  Roman SHIMANOVICH ,  Helming TAN

IPC: C07D519/00 ,  C07C275/02 ,  C07C57/10 ,  C07C55/12 ,  C07C57/145 ,  C07C55/10

CPC classification number: C07D519/00 ,  A61K31/52 ,  C07B2200/13 ,  C07C55/10 ,  C07C55/12 ,  C07C57/10 ,  C07C57/145 ,  C07C275/02

Abstract: Provided herein are novel polymorphic forms and co-crystals of a compound useful in the treatment, prevention, or amelioration of cancer. In particular, the invention provides polymorphs and co-crystals of 6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one, which is an inhibitor of c-Met.

Abstract translation: 本文提供了可用于治疗，预防或改善癌症的化合物的新型多晶型物和共晶体。 特别地，本发明提供了6 - {（1R）-1- [8-氟-6-（1-甲基-1H-吡唑-4-基）[1,2,4]三唑并[ 4,3-a]吡啶-3-基]乙基} -3-（2-甲氧基乙氧基）-1,6-萘啶-5（6H） - 酮，其是c-Met的抑制剂。